Form 8-K - Current report:
SEC Accession No. 0001437749-24-032365
Filing Date
2024-10-29
Accepted
2024-10-29 08:15:10
Documents
16
Period of Report
2024-10-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20241028_8k.htm   iXBRL 8-K 38634
2 EXHIBIT 99.1 ex_738863.htm EX-99.1 16252
7 nb01.jpg GRAPHIC 10980
  Complete submission text file 0001437749-24-032365.txt   210827

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nby-20241029.xsd EX-101.SCH 3403
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20241029_def.xml EX-101.DEF 11423
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20241029_lab.xml EX-101.LAB 15312
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20241029_pre.xml EX-101.PRE 11583
18 EXTRACTED XBRL INSTANCE DOCUMENT nby20241028_8k_htm.xml XML 2850
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 241402750
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)